Aim: To examine whether diabetic duration and insulin use are independently associated with the prognosis of critical limb ischemia (CLI) after endovascular therapy. Methods: We recruited 312 Japanese patients who underwent endovascular therapy for CLI. The outcome measures were major amputation and mortality. Cox proportional hazards regression analyses were performed. Results: The prevalence of diabetes mellitus (DM) was 69%, and 47% of the DM population were treated with insulin. DM patients with insulin use had hemoglobin A1c (HbA1c) of 7.5 1.3% and diabetic duration of 21 11 years, whereas those without insulin use had HbA1c of 6.6 1.4% and diabetic duration of 19 11 years. Follow-up period was 93 72 weeks; 55 patients underwent major amputations and 102 died. Diabetic duration and insulin use had significant associations with major amputation in each univariate model, with an unadjusted hazard ratio (HR) and 95% confidence interval (CI) of 1.019 [1.000, 1.039] in one-year increments and 2.321 [1.368, 3.938] , respectively. In the multivariate model, however, diabetic duration and insulin use were not significantly associated with limb prognosis, as HbA1c level was, with an adjusted HR [95% CI] of 1.332 [1.114, 1.593] in 1% increment. Mortality had no statistical association with any of these DM-related variables. Conclusion: Diabetic duration and insulin use were not independent risk factors for the prognosis of CLI after endovascular therapy.
Introduction
Critical limb ischemia (CLI) is a manifestation of peripheral arterial disease (PAD) that describes patients with chronic ischemic rest pain (Fontaine's stage ) or with ischemic skin lesions, either ulcers or gangrene (Fontaine's stage ). CLI has attracted increasing attention because it is associated with an extremely poor prognosis for both survival and limb salvage 1) . One year after the onset of CLI, 25% patients have died and another 25% have had the limb amputated; amputation-free survival after one year is estimated to be as low as 50%. Despite such a poor prognosis of CLI patients, its prognostic risk factors remains to be elucidated, which is in contrast to other cardiovascular diseases, including PAD other than CLI [2] [3] [4] [5] [6] .
Diabetes mellitus (DM), one of the major risk factors for other cardiovascular diseases, is prevalent among the CLI population and its presence has been believed to have some association with the prognosis of CLI. Although the evidence remains insufficient, there are at least two possible pathogeneses which could influence its prognosis: hyperglycemia and hyperinsulinemia.
Exposure to hyperglycemia is associated with impaired immune response and delayed wound healing as well as micro-and macroangiopathy [7] [8] [9] . These unfavorable phenomena could cause a poor prognosis of CLI and a few recent studies have shown that poor glycemic control evaluated with hemoglobin A1c (HbA1c) was significantly associated with limb loss 10, 11) ; however, no reports have ever discussed the diabetic duration. Long exposure to DM is associated with the progression of atherosclerosis 12) and it is well known that longer diabetic duration increases the risk of coronary heart disease and stroke in diabetic patients, independently of their glycemic control 13, 14) . It is reasonable to expect that diabetic duration, as well as glycemic control, would be independently associated with CLI prognosis.
Another aspect which is related to DM and could affect CLI prognosis is hyperinsulinemia. It has long been pointed out that insulin might induce endothelial dysfunction, increase smooth muscle cell proliferation, promote extracellular matrix deposition, alter lipid metabolism, and increase plasminogen activator inhibitor-1 levels, resulting in untoward imbalances in the fibrinolytic system [15] [16] [17] . Therefore, insulin therapy in DM patients, leading to hyperinsulinemia, could result in atherosclerosis and have an unfavorable effect on cardiovascular outcomes 17, 18) . One group recently reported that insulin use at the time of revascularization was associated with a poor prognosis in diabetic patients with CLI 19) but their study lacked adjustment for other DM-related conditions, that is, diabetic duration and glycemic control. Epidemiological studies have demonstrated that diabetic patients under insulin therapy often had a longer diabetic duration than those without insulin therapy and that they also tended to have a poorer glycemic control [20] [21] [22] . The poor prognosis of patients with insulin use might be therefore attributed to their long diabetic duration or poor glycemic control.
The aim of the current study was to assess whether diabetic duration and insulin use at the time of revascularization are independently associated with prognostic outcomes of CLI.
Subjects and Methods

Study population and definitions
We recruited and analyzed 312 consecutive Japanese patients who underwent endovascular therapy for CLI at Kansai Rosai Hospital, Hyogo, Japan, between 2003 and 2009. The diagnosis and management of CLI complied with the Transatlantic Inter-Society Consensus (TASC) 23) or its revised consensus, TASC 1) . All patients with chronic ischemic rest pain and/ or foot ulcer or gangrene were evaluated for limb isch-emia by angiographic study. Once they were diagnosed with CLI, we employed endovascular therapy as the first-choice procedure for revascularization, within the recommendations of TASC ( ). Major amputation, namely, above-the-ankle amputation, was considered when revascularization failed to relieve patients from rest pain or control their foot lesions.
DM was diagnosed when patients had been treated for DM or when they met the following criteria: fasting plasma glucose ≥ 7.0 mmol/l, regular plasma glucose ≥ 11.1 mmol/l, or HbA1c level 6.1%. Note that HbA1c was standardized by the Japan Diabetes Society 24) . Glycemic control was evaluated by HbA1c. Information on diabetic duration was obtained from the medical records or patient self-reports. Whether diabetic patients were using insulin or not was checked on admission for endovascular therapy. Hypertension was diagnosed as systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg or having been treated for hypertension. Dyslipidemia was defined as serum low-density lipoprotein cholesterol ≥ 100 mg/dl, high-density lipoprotein cholesterol 40mg/dl, triglycerides ≥ 150 mg/dl or having been treated for dyslipidemia. Infection was defined as the use of antibiotics. The outcome measures were major amputation and mortality, and the association of their baseline characteristics with these outcomes was analyzed.
Statistical analyses
Data are given as the means and standard deviations (SD) for continuous variables or as percentages for dichotomous variables. Differences between continuous variables in two groups were evaluated by the unpaired t test, while comparisons among more than two groups were tested by one-way analysis of variance (ANOVA). Dichotomous variables between two groups and among more groups were compared by Fisher's exact test and by Pearson's chi-square test, respectively. Limb salvage and survival were plotted using the Kaplan-Meier method and differences among groups were assessed by the log rank test.
The univariate Cox proportional hazards regression model was used to determine unadjusted associations of diabetic duration, as well as HbA1c levels and insulin use at the time of revascularization, with limb and life prognosis. To avoid data missing from the model, the variable of diabetic duration was considered to be 0 years when the patients did not have DM. When the unadjusted associations of these DM-related variables were statistically significant, they were entered into multivariate Cox proportional hazards regression models, together with the other significant variables in univariate analyses to reveal independent association with the outcomes. Hazard ratios (HR) and 95% confidence intervals (CI) are reported. A p value 0.05 was considered significant. Statistical analyses were performed using IBM SPSS Statistics Version 19 (SPSS Inc.).
Results
Characteristics of study population
Baseline characteristics of the participants are shown in Table 1 . The prevalence of DM was 69% (n 215), and 47% (n 100) of the DM population was treated with insulin. DM patients who were being treated with insulin had a significantly higher HbA1c than those without (7.5 1.3% vs 6.6 1.4%, p 0.001), whereas the diabetic duration of insulin users was slightly, but not significantly, longer than that of non-insulin users (21 11 years vs. 19 11 years, p 0.142). Two hundreds and nine patients (67%) had infrapopliteal lesions revascularized. Seven patients (2%) underwent bypass surgery within a month after primary endovascular therapy.
The follow-up period of the study population was 93 72 weeks (1.8 1.4 years); 55 patients (18%) underwent major amputations and 102 (33%) died. The leading cause of death was cardiac and vascular disease (n 45), followed by infection (n 35). In the unadjusted Cox proportional hazards regression model, DM was significantly associated with major amputation (HR 2.419 [1.184, 4.942]), but not with mortality (HR 0.982 [0.646, 1.492]). Fig. 1 shows Kaplan-Meier estimates of major amputation. There were statistically significant differences in the limb salvage rate among groups classified according to diabetic conditions. First, as shown in Fig. 1A , diabetic patients were divided into two subgroups according to the length of diabetic duration, with the use of its median value (20 years), and the limb prognosis of each subgroup was compared to that of non-diabetic patients. As a result, those with a longer diabetic duration had a significantly higher major amputation rate than non-diabetic patients ( p 0.012 in log rank test). Note that the statistical significance of this increased risk persisted even after Bonferroni's correction was applied. On the other hand, the p value in the log rank test comparing diabetic patients with a shorter duration and non-diabetic patients was 0.036, which did not reach statistical significance after Bonferroni's correction. Second, when diabetic patients were classified into two groups according to their HbA1c level, using its median value (6.8%) ( Fig. 1B) , diabetic patients with higher HbA1c had inferior limb salvage to non-diabetic patients ( p 0.001), which was still statistically significant after Bonferroni's correction. Meanwhile, there was no significant difference in the major amputation rate between diabetic patients with lower HbA1c and nondiabetic patients ( p 0.452). Finally, we divided the DM population in accordance with insulin use (Fig. 1C) . As a result, although diabetic patients without insulin use had no significant difference in limb prognosis from non-diabetic patients ( p 0.164), dia- betic patients who were treated with insulin had significantly poorer limb prognosis than non-diabetic patients ( p 0.001).
Limb prognosis and diabetic condition
Indeed, these DM-related conditions, that is, diabetic duration, HbA1c level, and insulin use, had statistically significant associations with major amputation in the univariate Cox proportional hazards regression model. Their unadjusted HR were 1.019 [1.000, 1.039] in one-year increment, 1.348 [1.160, 1.567] in 1% increment, and 2.321 [1.368, 3.938], respectively ( Table 2) . All of these DM-related variables were therefore entered into the multivariate model as well as other baseline characteristics significantly associated with limb loss in each univariate model. The multivariate model revealed that HbA1c, but not diabetic duration nor insulin use, was independently associated with limb prognosis. The adjusted HR of HbA1c was 1.332 [1.114, 1.593] in 1% increment, whereas those of diabetic duration and insulin use were 0.997 [0.973, 1.021] in one-year increment and 1.375 [0.751, 2.517], respectively, both of which lost statistical significance. Independent variables other than DM-related conditions were Fontaine's stage, infection, and hemodialysis ( Table 2) .
It should be remembered that these analyses were performed with interpretation of the diabetic duration variable of non-diabetic patients as 0 years, which was based on the hypothesis of the continuity of this variable between diabetic and non-diabetic patients. To confirm no independent association of the variable with major amputation, we additionally performed category analysis which did not rely on this hypothesis. In brief, diabetic patients were classified into four groups using the median values of diabetic duration and HbA1c, and were compared with the non-diabetic population in the multivariate model. As shown in Fig. 2 , the model revealed that the two diabetic subgroups with higher HbA1c had a significantly increased risk of major amputation than the non-DM group regardless of their diabetic duration. Meanwhile, the adjusted HR of the diabetic subgroups with lower HbA1c relative to the non-diabetic group did not reach statistical significance, even if they had a longer diabetic duration. These results indicate that major amputation is not associated with diabetic duration, but rather with HbA1c. Fig. 3 shows Kaplan-Meier estimates of survival, which revealed no statistically significant differences in life prognosis among the subgroups classified according to diabetic conditions. First, both diabetic patients with a longer duration and those with a shorter duration had no significant difference from non-diabetic patients, with p values in the log rank test of 0.558 and 0.322, respectively (Fig. 3A) . Second, as shown in Fig. 3B , the survival rate of diabetic patients with higher HbA1c as well as those with lower HbA1c was not significantly different from non-diabetic patients ( p 0.753 and 0.672). Finally, classification in accordance with insulin use did not produce any significant difference in mortality among groups, with p values of 0.367 (diabetic patients with insulin use vs. non-diabetic patients) and 0.477 (diabetic patients without insulin use vs. non-diabetic patients) in the log rank test, respectively (Fig. 3C) . insulin use duration � 20 years HbA1c � 6.8%
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Fig. 3. Kaplan-Meier estimates of survival rate in CLI patients undergoing endovascular therapy
The DM population was divided into two groups in accordance with diabetic duration (A), HbA1c level (B) and insulin use (C). Diabetic duration (A) and HbA1c level (B) were categorized into two classes using the median values (20 years and 6.8%). No statistically significant difference was found among groups.
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In the univariate Cox proportional hazards regression model, the unadjusted HR of diabetic duration, HbA1c, and insulin use were 1.006 [0.991, 1.021] in one-year increment, 0.908 [0.786, 1.048] in 1% increment, and 0.714 [0.462, 1.104], all of which failed to reach statistical significance.
Discussion
DM is a major risk factor of atherosclerotic diseases, such as ischemic heart disease, cerebral infarction and PAD. As is well known, however, patients with DM are a heterogeneous population; diabetic duration and glycemic control differ among patients, and some patients require insulin therapy while others do not. It would not be surprising if these heterogeneous diabetic conditions produced a difference in cardiovascular prognosis among the DM population.
A number of studies have revealed that a long diabetic duration increases the risk of fatal or non-fatal ischemic heart disease and cerebral infarction in diabetic patients, independently of their glycemic control 13, 14) . Its association with the prognostic outcomes of PAD, especially CLI, however, remains so far uninvestigated. The current study revealed that diabetic duration was not independently associated with CLI prognosis as glycemic control was, although it was apparently associated with limb prognosis in the unadjusted model.
We also investigated in the current study an independent association of insulin use with the prognostic outcome of CLI. It has long been pointed out that insulin might cause atherosclerosis [15] [16] [17] and some researchers have argued that insulin therapy, leading to hyperinsulinemia, would have an unfavorable effect on cardiovascular outcomes 17, 18) . Meanwhile, other groups have countered that insulin has an anti-inflammatory effect and would be protective against atherosclerosis, the progression of which is known to be associated with inflammatory responses 25) . Our current study, however, revealed that insulin use has no independent association with unfavorable or favorable prognostic outcomes in CLI patients undergoing endovascular therapy.
A few recent studies reported that poor glycemic control 10, 11) and insulin use 19) were associated with limb prognosis in CLI patients, but each study adopted only one DM-related variable and lacked adjustment for other diabetic conditions, including diabetic duration. DM patients under insulin therapy would tend to have a longer diabetic duration and a poorer glycemic control. Furthermore, patients with a long diabetic duration, regardless of insulin use, might tend to have poor glycemic control. These DM-related variables, therefore, would be confounding and dependent on one another. To reveal their independent associations with the prognosis in CLI patients, it is necessary to avoid analyzing these DM-related variables separately and this is the first report analyzing these three variables at the same time.
In the current study, we employed HbA1c as a marker of glycemic control and revealed that HbA1c had a significant association with limb prognosis, independently of diabetic duration and insulin use; however, HbA1c could be influenced not only by recent glycemic control but also by anemia. Some may be concerned about whether anemia could modify the outcome. Furthermore, since HbA1c reflects the status of glycemic control over the previous few months, others may point out that it remains unclear whether hyperglycemia at the time of revascularization for CLI could be associated with major amputation, if HbA1c was used for analysis. To clarify these points, we additionally performed multivariate Cox proportional hazard analysis into which both hemoglobin (g/dl) and fasting plasma glucose (mmol/l) were entered instead of HbA1c. The model was adjusted for the other variables independently associated with limb prognosis, that is, Fontaine's stage , infection, and hemodialysis. As a result, fasting plasma glucose, as well as Fontaine's stage , infection and hemodialysis, had a statistically significant association with major amputation, with an adjusted HR of 1.079 [1.020, 1.152] in 1 mmol/l increment. On the other hand, hemoglobin was not associated with major amputation; its adjusted HR was 0.993 [0.840, 1.038] in 1 g/dl increment (data not shown). These findings suggest that hyperglycemia at the time of revascularization for CLI, rather than anemia at that time, has an independent association with limb prognosis.
Our current findings will give two clinical indications as follow. First, our findings will contribute to the future establishment of prognostic risk assessment in CLI patients, especially those undergoing endovascular therapy. Recent studies have confirmed the effectiveness of revascularization with endovascular therapy for CLI; the outcomes seem similar to surgical revascularization even in infrapopliteal segments 26, 27) . Because of its minimal invasiveness, endovascular therapy is ideally suited even to those at high risk for bypass surgery, including patients with DM, and is now widely used for their revascularization. However, some patients are still condemned to a poor prognosis even after endovascular therapy. There is urgent need to reveal the preoperative factors associated with their prognosis. Our findings ascertained that poor glyce-mic control was an independent risk factor of major amputation. In contrast, diabetic duration and insulin use were not independent factors and therefore the use of these two DM-related variables for risk assessment would be misleading. Clinicians should instead adopt poor glycemic control as a preoperative risk factor for major amputation. It is also important to recognize that none of these DM-related variables were associated with the risk of mortality in CLI patients undergoing endovascular therapy.
Second, our findings increase the hope for prognostic improvement of CLI. The current study confirmed that poor glycemic control increased major amputation risk regardless of the diabetic duration and insulin use. Glycemic control is a correctable variable and correction of poor glycemic control can lead to the improvement of limb prognosis in DM patients even with a long diabetic duration or insulin use. Our findings thus encourage a subsequent prospective trial investigating the effect of correcting glycemic control on the prognostic outcome.
In conclusion, diabetic duration and insulin use were not independent risk factors for the prognosis of CLI patients undergoing endovascular therapy, which was in contrast to an independent association of poor glycemic control with major amputation. A further prospective investigation is required to determine whether intervention in glycemic control improves prognosis regardless of diabetic duration and insulin use.
